Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress ("ESMO")

Stock Information for Zymeworks Inc.

Loading

Please wait while we load your information from QuoteMedia.